461 related articles for article (PubMed ID: 23633457)
1. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.
Linehan WM; Rouault TA
Clin Cancer Res; 2013 Jul; 19(13):3345-52. PubMed ID: 23633457
[TBL] [Abstract][Full Text] [Related]
2. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
Tong WH; Sourbier C; Kovtunovych G; Jeong SY; Vira M; Ghosh M; Romero VV; Sougrat R; Vaulont S; Viollet B; Kim YS; Lee S; Trepel J; Srinivasan R; Bratslavsky G; Yang Y; Linehan WM; Rouault TA
Cancer Cell; 2011 Sep; 20(3):315-27. PubMed ID: 21907923
[TBL] [Abstract][Full Text] [Related]
3. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.
Yang Y; Lane AN; Ricketts CJ; Sourbier C; Wei MH; Shuch B; Pike L; Wu M; Rouault TA; Boros LG; Fan TW; Linehan WM
PLoS One; 2013; 8(8):e72179. PubMed ID: 23967283
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
[TBL] [Abstract][Full Text] [Related]
6. Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes.
Podkalicka P; Mucha O; Kruczek S; Biela A; Andrysiak K; Stępniewski J; Mikulski M; Gałęzowski M; Sitarz K; Brzózka K; Józkowicz A; Dulak J; Łoboda A
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31963199
[TBL] [Abstract][Full Text] [Related]
7. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
[TBL] [Abstract][Full Text] [Related]
8. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
Ooi A
Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
[TBL] [Abstract][Full Text] [Related]
9. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism.
Bardella C; Olivero M; Lorenzato A; Geuna M; Adam J; O'Flaherty L; Rustin P; Tomlinson I; Pollard PJ; Di Renzo MF
Mol Cell Biol; 2012 Aug; 32(15):3081-94. PubMed ID: 22645311
[TBL] [Abstract][Full Text] [Related]
10. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase.
Frezza C; Zheng L; Folger O; Rajagopalan KN; MacKenzie ED; Jerby L; Micaroni M; Chaneton B; Adam J; Hedley A; Kalna G; Tomlinson IP; Pollard PJ; Watson DG; Deberardinis RJ; Shlomi T; Ruppin E; Gottlieb E
Nature; 2011 Aug; 477(7363):225-8. PubMed ID: 21849978
[TBL] [Abstract][Full Text] [Related]
11. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
Chan E; Rabban JT; Mak J; Zaloudek C; Garg K
Am J Surg Pathol; 2019 Sep; 43(9):1170-1179. PubMed ID: 31162287
[TBL] [Abstract][Full Text] [Related]
12. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
13. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
[TBL] [Abstract][Full Text] [Related]
14. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
15. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
Xie H; Valera VA; Merino MJ; Amato AM; Signoretti S; Linehan WM; Sukhatme VP; Seth P
Mol Cancer Ther; 2009 Mar; 8(3):626-35. PubMed ID: 19276158
[TBL] [Abstract][Full Text] [Related]
16. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
17. Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings.
Harrison WJ; Andrici J; Maclean F; Madadi-Ghahan R; Farzin M; Sioson L; Toon CW; Clarkson A; Watson N; Pickett J; Field M; Crook A; Tucker K; Goodwin A; Anderson L; Srinivasan B; Grossmann P; Martinek P; Ondič O; Hes O; Trpkov K; Clifton-Bligh RJ; Dwight T; Gill AJ
Am J Surg Pathol; 2016 May; 40(5):599-607. PubMed ID: 26574848
[TBL] [Abstract][Full Text] [Related]
18. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
19. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
Bayley JP; Launonen V; Tomlinson IP
BMC Med Genet; 2008 Mar; 9():20. PubMed ID: 18366737
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.
Ashrafian H; O'Flaherty L; Adam J; Steeples V; Chung YL; East P; Vanharanta S; Lehtonen H; Nye E; Hatipoglu E; Miranda M; Howarth K; Shukla D; Troy H; Griffiths J; Spencer-Dene B; Yusuf M; Volpi E; Maxwell PH; Stamp G; Poulsom R; Pugh CW; Costa B; Bardella C; Di Renzo MF; Kotlikoff MI; Launonen V; Aaltonen L; El-Bahrawy M; Tomlinson I; Pollard PJ
Cancer Res; 2010 Nov; 70(22):9153-65. PubMed ID: 20978192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
